Search Results
Your search for ASCO matches 21344 pages
Showing 18001 - 18050Discussions About the Cost of Cancer Care Are Still Uncommon
Patients with cancer are extremely interested in discussing the cost of treatment, especially their share of the cost, but some oncologists are still hesitant to enter into these conversations, according to a study reported at the National Comprehensive Cancer Network (NCCN) 2014 Conference.1 “We...
ASCO Committee Defines Clinically Meaningful Goals for Clinical Trials in Pancreas, Breast, Lung, and Colorectal Cancers
The ASCO Cancer Research Committee recently convened four disease-specific working groups—in pancreas, breast, lung, and colon cancers—to “consider the design of future clinical trials that would produce results that are clinically meaningful to patients.” An ASCO perspective statement, reported in ...
Setting a ‘Moon Shots’ Goal to Drastically Reduce Cancer Mortality Over the Next Decade
In 2012, just 1 year after taking the reins as President of The University of Texas MD Anderson Cancer Center, Ronald A. DePinho, MD, announced his plans to launch the Moon Shots Program, the most ambitious endeavor undertaken by the cancer center to dramatically accelerate the pace of reducing...
James P. Allison, PhD, Receives 2014 Canada Gairdner International Award
The Gairdner Foundation of Canada has named James P. Allison, PhD, for one of its 2014 Canada Gairdner International Awards. Dr. Allison is Chair and Professor of Immunology at The University of Texas MD Anderson Cancer Center in Houston. The honor, announced recently by the Gairdner Foundation,...
AACR Honors Douglas Hanahan, PhD, With AACR Lifetime Achievement in Cancer Research Award
Douglas Hanahan, PhD, Director of the Swiss Institute for Experimental Cancer Research at the Swiss Federal Institute of Technology, in Lausanne, Switzerland, was recently honored with the 11th annual American Association for Cancer Research (AACR) Lifetime Achievement in Cancer Research. The award ...
Shelagh Tippet-Fagyas Named President of The Leukemia & Lymphoma Society of Canada
The Leukemia & Lymphoma Society recently announced that its Canadian affiliate, The Leukemia & Lymphoma Society of Canada, has named Shelagh Tippet-Fagyas as its new President. Ms. Tippet-Fagyas will lead the Canadian Society in its efforts to find cures and ensure access to therapies for...
Help Your Patients Understand the Latest Research to be Highlighted at the 2014 ASCO Annual Meeting
Direct your patients to Cancer.Net, ASCO’s patient information website, to find easy-to-read summaries of studies released on May 14 in advance of this year’s Annual Meeting. In addition, encourage them to listen to a panel discussion and Q&A session about these latest advances in a recording...
Visit the Conquer Cancer Foundation Donor Lounge at the ASCO Annual Meeting
The work that we do at the Conquer Cancer Foundation would not be possible without the support of generous donors who share our vision to create a world free from the fear of cancer. Conquer Cancer Foundation supporters are invited to visit the Donor Lounge during the ASCO Annual Meeting, held May...
ASCO Launches New Resources for Providers and Patients to Address Link Between Obesity and Cancer
As the obesity epidemic takes its toll on the nation’s health, ASCO is making strides to address this growing concern as it relates to cancer. ASCO has developed a suite of educational resources designed to help oncology providers educate their patients about the negative effects of obesity on...
Conquer Cancer Foundation of ASCO Young Investigator Award Recipients Supported by the Strike 3 Foundation
Sarah K. Tasian, MD (2011 Young Investigator Award) The Children’s Hospital of Philadelphia Predicting Biochemical and Genetic Responses to JAK Inhibitor Therapy in Patients With CRLF2-Overexpressing Acute Lymphoblastic Leukemia Kasey Leger, MD (2012 Young Investigator Award) University of...
Conquer Cancer Foundation and Strike 3 Foundation Work Together to Conquer Pediatric Cancers
Envision a world where a diagnosis of pediatric cancer is met with the same reaction as a diagnosis of the common cold. In this idyllic world, the word “cancer” no longer carries with it the same traumatic response or stigma that it does today. This hopeful vision is what drives Craig Breslow in...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
Centers for Disease Control and Prevention Awards Grants of More Than $1.25 Million to College of American Pathologists
The College of American Pathologists (CAP) has been awarded two grants from the Centers for Disease Control and Prevention (CDC). The funding, totaling more than $1.25 million, will be used to improve the adoption of evidence-based laboratory testing guidelines and to standardize reporting of...
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Announces Faculty Appointments, Grants
Noah M. Hahn, MD, has been selected as Associate Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Before joining Johns Hopkins, Dr. Hahn was the Director of the Genitourinary Medical Oncology Program at Indiana University. He is an...
Project Data Sphere: Megadata in the Cloud Could Speed Clinical Trials Here on Earth
Project Data Sphere, which launched on April 8, is a “giant digital laboratory, an enormous library containing data about tens of thousands of patients and hundreds of clinical trials, all of which will be in the public domain,” said Martin J. Murphy, Jr, DMedSc, PhD, FASCO, Chief Executive Officer ...
Michael S. Gordon, MD, Named Medical Director for Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare
Michael S. Gordon, MD, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare in Phoenix. Dr. Gordon will oversee the center’s phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale...
Researchers Cornelia Ulrich, PhD, and Bruce A. Edgar, PhD, Join Huntsman Cancer Institute
Cornelia Ulrich, PhD, and Bruce A. Edgar, PhD, scholars in the fields of cancer prevention and molecular biology, respectively, will join Huntsman Cancer Institute at the University of Utah as early as September 1, 2014. Dr. Ulrich is currently serving as a Director of the National Center for...
Phase III Trial Reports Focused Ultrasound Reduces Cancer Pain
A phase III clinical trial has shown that noninvasive magnetic resonance-guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited. The results were published recently in the Journal of...
Getting It Right in the End: Individualization of Care for Patients With Rectal Cancer
Data from trials conducted mostly in the 1970s and 1980s established the paradigm that optimal treatment of rectal cancer requires a combination of radiation therapy, chemotherapy, and surgery.1 Virtually all of these trials, however, demonstrated that radiotherapy added only to the local control...
Neoadjuvant Chemotherapy Without Routine Radiotherapy Shows Promise in Patients With Locally Advanced Rectal Cancer
In a pilot study reported in the Journal of Clinical Oncology, Deborah Schrag, MD, MPH, and colleagues from Memorial Sloan Kettering Cancer Center, New York, assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with selective use of...
FDA Discourages Use of Laparoscopic Power Morcellation for Removal of Uterus or Uterine Fibroids
In a safety communication notice issued recently, the U.S. Food and Drug Administration (FDA) discouraged the use of laparoscopic power morcellation for the removal of the uterus (hysterectomy) or uterine fibroids (myomectomy) in women because, based on an analysis of currently available data, it...
Beyond the Cystoscope: Thinkers and Technicians
I have spent my career working with urologists. Over a long period of time, I have concluded that they are fine and interesting people who work hard, live well, support interesting hobbies, generally take good care of their families, and are very enjoyable company at parties. The recent discussion...
Demanding More From Clinical Trials
“The function of the formal controlled clinical trial is to separate the relative handful of discoveries that prove to be true advances in therapy from a legion of false leads and unverifiable clinical impressions, and to delineate in a scientific way the extent of and the limitations that attend...
Cancer Chemotherapy Use During Pregnancy
INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this installment, National Toxicology Program scientists Kembra L. Howdeshell, PhD, and Michael D. Shelby, PhD, discuss a recently completed monograph that reviews the published data on...
Volasertib Granted Orphan Drug Designation for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to volasertib for acute myeloid leukemia. Volasertib is currently being evaluated in a phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for...
Supplemental New Drug Application Submitted for Ibrutinib in CLL
Pharmacyclics, Inc, and Janssen Biotech, Inc, have announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multicenter, open-label phase III RESONATE study, a head-to-head comparison of single-agent ibrutinib ...
FDA Approves Mercaptopurine Oral Suspension for Acute Lymphoblastic Leukemia
On April 28, 2014, the U.S. Food and Drug Administration approved a 20 mg/mL oral suspension of mercaptopurine (Purixan) indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen. Successive clinical trials have demonstrated that mercaptopurine ...
FDA Proposes to Extend Its Tobacco Authority to Additional Tobacco Products, Including E-Cigarettes
On April 24, 2014, as part of its implementation of the Family Smoking Prevention and Tobacco Control Act signed by the President in 2009, the U.S. Food and Drug Administration (FDA) proposed a new rule that would extend the agency’s tobacco authority to cover additional tobacco products. Products ...
FDA Approves First HPV Test for Primary Cervical Cancer Screening
The U.S. Food and Drug Administration (FDA) approved the first human papillomavirus (HPV) DNA test that can be used as a primary cervical cancer screening test for women aged 25 years and older. The test also can provide information about the patient’s risk for developing cervical cancer in the...
FDA Approves Siltuximab for Rare Castleman’s Disease
The U.S. Food and Drug Administration (FDA) has approved siltuximab (Sylvant injection) for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV)-negative and human herpes virus-8 (HHV-8)-negative. Multicentric Castleman’s disease is a rare...
FDA Approves Ceritinib for Late-Stage Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ceritinib (Zykadia) for patients with a metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who were previously treated with crizotinib (Xalkori). Ceritinib is an ALK tyrosine kinase...
Personalized Cancer Fatigue Care: ASCO Clinical Practice Guideline Adaptation
The majority of cancer survivors report different levels of cancer-related fatigue that can last for many years after completion of therapy. The American Society of Clinical Oncology has made a valuable contribution to care of adult cancer survivors by providing a simple and effective clinical...
ASCO Releases Adapted Guideline on Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer
A majority of cancer patients experience some level of fatigue during the course of their treatment, and approximately 30% contend with persistent fatigue for years after treatment. Fatigue is among the most common and distressing long-term effects of cancer treatment and significantly affects...
Meta-Analysis Shows Survival Benefit of Preoperative Chemotherapy in NSCLC
In a systematic review and individual patient meta-analysis reported in The Lancet,1 the NSCLC Meta-analysis Collaborative Group found that neoadjuvant therapy for non–small cell lung cancer (NSCLC) was associated with a significant 13% reduction in risk of death. Significant benefits in...
Postmastectomy Radiotherapy Benefits Women With Breast Cancer That Has Spread to One to Three Lymph Nodes
In women with breast cancer who had between one and three positive lymph nodes, radiotherapy reduced the recurrence rate by 32% and the breast cancer death rate by 20%. Giving radiotherapy to these women led to nearly 12 fewer recurrences of breast cancer per 100 women after 10 years, and eight...
One Step Forward
ASCO has taken the field of psychosocial oncology a step forward in the right direction by providing guidelines for oncologists to direct care of the two most common emotional symptoms that patients experience: anxiety and depression.1 It is fair to say that all patients experience these...
ASCO Releases Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
Detection of depression is suboptimal, and its severity is underestimated in the general population, but it is known psychiatric disorders are more common in patients with cancer than in those with any other chronic illness. Although studies in cancer patients have yielded varying figures, it is...
The Affordable Care Act: NCCN Panelists Rate It ‘Average’
Oncologists and third-party payers are already experiencing changes as a result of the Affordable Care Act, which earned an “average” rating by a panel of providers, payers, and patients assembled at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood,...
Andrew D. Zelenetz, MD, PhD, on Treating the Elderly Lymphoma Patient With Elevated Bilirubin
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), lymphoma expert and NCCN Panel Chair on Lymphoma, Andrew D. Zelenetz, MD, PhD, fielded questions from oncologists. The ASCO Post was there to capture his recommendations for a common clinical scenario—treating the...
Belinostat Moves Forward in Trials for Two Aggressive Cancers
In February, the U.S. Food and Drug Administration (FDA) granted belinostat (Beleodaq), a targeted histone deacetylase (HDAC) inhibitor, priority review status based on a pivotal phase II trial in peripheral T-cell lymphoma. Just 1 month later, researchers at the National Cancer Institute (NCI) in...
Workshops Train Community Cancer Center Nurses and Administrators to Implement Clinical Trials
A series of new workshops are teaching nurses and administrators from community hospital cancer programs how to promote, run, and improve their institutions’ clinical trials. The training focuses on specific skills and tasks, offers postcourse support and aims for long-term, measurable outcomes,...
FGFR Inhibitors of Interest in Bladder and Lung Cancer
Fibroblast growth factor receptor (FGFR) inhibitors are an emerging area of interest in cancer therapeutics. Studies presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego provided early encouraging data for two investigational pan-FGFR inhibitors for the...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
Survival Analysis of Contralateral Prophylactic Mastectomy Sparks Discussion
Contralateral prophylactic mastectomy improved breast cancer patients’ odds of overall survival by 23% compared with single mastectomy alone, according to a retrospective analysis of nearly 170,000 patients in a U.S. database, but surgical breast cancer specialists warned that the data needed to be ...
NCCN Clinical Practice Guidelines in Oncology: 2014 Updates
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held recently in Hollywood, Florida, NCCN Panel members presented updates for several tumor types, briefly summarized here. For a more complete description of all updates, visit www.nccn.org. Breast Cancer Guidelines ...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
ASCO Develops New Strategy to Increase Value in Cancer Care
Last January, ASCO held a leadership summit in Washington, DC, with representatives from the pharmaceutical industry, insurance payers, patient advocates, and physicians to address the skyrocketing costs of new drugs and technologies used in the diagnosis and treatment of cancer. Although costs are ...
Guidelines for Chemotherapy-Induced Neuropathy: The Known Unknowns
It is a tribute to the advances in supportive care that peripheral neuropathy, along with fatigue, has become the most vexing management challenge in cancer patients receiving chemotherapy. The successes of modern antiemetic regimens and white blood cell growth factor support have radically altered ...
ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
ASCO has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology.1 The guidelines resulted from the efforts of an expert panel, with representation from the fields of...
About the Artist
Keith Witmer received his Bachelor’s degree in Fine Arts from Otis/Parsons School of Design. He subsequently launched his career in advertising and publication with a commanding presence, initially using pen and ink and scratchboard mediums. Working with clients such as FedEx, Apple Computer,...
